Top View
- Neratinib Chapter
- Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
- Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
- Neratinib Plus Paclitaxel Vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer the Nefert-T Randomized Clinical Trial
- A Study of Neratinib Plus Capecitabine Versus
- Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
- PF-00299804 Bosutinib Axitinib
- The Characterization, Management, and Future Considerations for Erbb-Family TKI-Associated Diarrhea
- Neratinib (Nerlynx®) EOCCO POLICY
- Ultra Performance Liquid Chromatography Tandem Mass Spectrometric Method Development and Validation for Determination of Neratinib in Human Plasma
- NERLYNX Safely and Effectively
- Pfizer Worldwide Research & Development
- Early Stability and Late Random Tumor Progression of a HER2-Positive
- HDAC Inhibitors Enhance Neratinib Activity and When Combined Enhance the Actions of an Anti-PD-1 Immunomodulatory Antibody in Vivo
- Hyperactivation of Mtorc1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers Dhivya R
- PIK3CA Alterations and Benefit with Neratinib: Analysis from the Randomized, Double-Blind, Placebo-Controlled, Phase III Extenet Trial Stephen K
- Transcriptome Analysis of Neratinib Treated HER2 Positive Cancer
- NERLYNX (Neratinib) Immediate Release, Film-Coated Tablets for Oral Administration Contain 40 Mg of Neratinib, Equivalent to 48.31 Mg Neratinib Maleate
- Nerlynx 40Mg, INN-Neratinib
- Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
- T-DM1) with Neratinib in Women with Metastatic HER2- Positive Breast Cancer Jame Abraham,1 Shannon L
- HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified Or Mutant Lung Cancers
- Using Combination Drug Therapy to Advance the Effect of the Treatment
- Comparative Analysis of Drug Response and Gene Profiling Of
- Antineoplastic Kinase Inhibitors: a New Class of Potent Anti-Amoebic Compounds
- The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
- Tyrosine Kinase Inhibitors - Oral
- A Phase I Study with Neratinib (HKI-272), an Irreversible Pan Erbb Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors Kwok-K.Wong,1Paula M
- Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-Amplified Metastatic Breast Cancer
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- 208051Orig1s000
- HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2- Positive and HER2-Mutated Breast Cancer
- Neoadjuvant Neratinib Promotes Ferroptosis and Inhibits Brain
- Pharmacy Medical Necessity Guidelines: Oral Cancer Medications Effective: October 1, 2021
- Treatment and Side Effects
- Integrative in Vivo Drug Testing Using Gene Expression Signature
- Nerlynx® (Neratinib) (Oral) Document Number: IC-0311 Last Review Date: 03/03/2020 Date of Origin: 08/29/2017 Dates Reviewed: 08/2017, 07/2018, 07/2019, 03/2020
- RFP: February 11, 2021
- HER2 Splice Variants in Breast Cancer: Investigating Their Impact on Diagnosis and Treatment Outcomes
- Master List of All CPT to Include Claims Only Codes for Any UM
- HER2-Mutated Breast Cancer Responds to Treatment with Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor
- Anti-Tumoral Activity of Single and Combined Regorafenib Treatments In
- A Gene Expression Profile Indicative of Early Stage HER2 Targeted Therapy